Cleared Traditional

K170848 - Alzair Allergy Blocker (FDA 510(k) Clearance)

Class II Ear, Nose, Throat device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K170848 · Nasaleze International, Ltd. · Ear, Nose, Throat device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jun 2017
Decision
85d
Days
Class 2
Risk

K170848 is an FDA 510(k) clearance for the Alzair Allergy Blocker. Classified as Cream, Nasal, Topical, Mechanical Allergen Particle Barrier (product code NUP), Class II - Special Controls.

Submitted by Nasaleze International, Ltd. (Douglas, IM). The FDA issued a Cleared decision on June 14, 2017 after a review of 85 days - a notably fast clearance cycle.

This device falls under the Ear, Nose, Throat FDA review panel, regulated under 21 CFR 880.5045 - the FDA ear, nose and throat device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Nasaleze International, Ltd. devices

Submission Details

510(k) Number K170848 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 21, 2017
Decision Date June 14, 2017
Days to Decision 85 days
Submission Type Traditional
Review Panel Ear, Nose, Throat (EN)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
4d faster than avg
Panel avg: 89d · This submission: 85d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code NUP Cream, Nasal, Topical, Mechanical Allergen Particle Barrier
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 880.5045
Definition The Device Is Intended To Promote Alleviation Of Mild Allergic Symptoms Triggered By The Inhalation Of Various Allergens.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Ear, Nose, Throat devices follow this clearance model.